- This event has passed.
Webinar: Unraveling Neurological Diseases
March 20 @ 1:00 pm - 2:00 pm UTC-4
Unraveling Neurological Diseases: Biomarker Discovery With Advanced Multiomics and Model Organisms
March 20, 2024 — 10am (PT) | 1pm (ET) | 6pm (CET)
Presented by GenomeWeb
CLN3 Batten disease, a pediatric lysosomal storage disorder, affects approximately 1 in 100,000 individuals, making it the most common pediatric neurodegenerative disorder worldwide. Yet a lack of etiological insights and translatable biomarkers has significantly slowed the development of therapies.
In this webinar, Jon Brudvig, director of discovery research and gene therapy at Amicus Therapeutics, will discuss how Sanford Research recently discovered new CLN3-related biomarkers and molecular insights in a Yucatan Minipig disease model, utilizing a novel multi-omics approach powered by the Seer Proteograph workflow.
Speakers will discuss:
- The most exhaustive in-depth multi-omics profiling ever conducted on serum from a porcine model with thousands of proteins, over 10,000 peptides, and metabolome data.
- Advanced neurodegenerative treatment research for targeted therapies, with previously impossible insights into novel CLN3 disease state biomarkers and perturbed pathways.
- How Seer’s species-agnostic workflow efficiently processes low-volume samples from model organisms.
Speakers
|
Jon Brudvig, Ph.D. Director of Discovery Research and Gene Therapy, Amicus Therapeutics |
|
Jon Brudvig is the director of discovery research and gene therapy at Amicus Therapeutics, where he leads initiatives in biomarker discovery and the preclinical development of gene therapies for rare diseases. He is also an assistant professor in pediatrics at the University of South Dakota and works with the Weimer Lab at Sanford Research, where his primary research focus is on developing a better understanding of Batten disease biology, leading to novel therapeutic strategies. Brudvig holds a doctorate in basic biomedical sciences from the University of South Dakota. |
|
|
Aaron Gajadhar, Ph.D. Director of Strategic Applications, Seer Inc. |
|
Aaron Gajadhar received his doctorate in medical biophysics at the University of Toronto. Following his graduate training, he completed a postdoctoral fellowship at MIT with Forest White at the Koch Institute for Integrated Cancer Research. In 2015, Gajadhar joined Merrimack Pharmaceuticals in Cambridge, where he worked as a senior scientist in early discovery. Gajadhar joined Thermo Fisher Scientific in San Jose in 2017 and was involved in developing new LC-MS technologies for the proteomics market. Since 2021, Gajadhar worked at Seer in roles spanning program management for proof-of-principle and collaborations, software product management, and, more recently, overseeing the strategic applications group to explore novel uses of Seer’s Proteograph Product Suite. |
|